Jazz Pharmaceuticals To Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
JAZZ•Deal terms and structure
Jazz Pharmaceuticals PLC said it will acquire Actio Biosciences, expanding its rare epilepsy portfolio.
- Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront, plus up to $500 million contingent.
- Actio Biosciences will spin out a new private entity, and Jazz will receive a minority stake.
- Jazz said it will fund the deal with cash on hand and existing financing facilities.
- The deal is expected to close by Q4 2026, subject to conditions.
